WO2009119538A1 - Nouveau polypeptide ayant une activité épimérase, son procédé de production, et utilisation - Google Patents

Nouveau polypeptide ayant une activité épimérase, son procédé de production, et utilisation Download PDF

Info

Publication number
WO2009119538A1
WO2009119538A1 PCT/JP2009/055742 JP2009055742W WO2009119538A1 WO 2009119538 A1 WO2009119538 A1 WO 2009119538A1 JP 2009055742 W JP2009055742 W JP 2009055742W WO 2009119538 A1 WO2009119538 A1 WO 2009119538A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
sugar residue
enzyme activity
oligosaccharide
reaction
Prior art date
Application number
PCT/JP2009/055742
Other languages
English (en)
Japanese (ja)
Inventor
進 伊藤
秀典 田口
淳 和崎
武志 瀬野浦
純 渡辺
Original Assignee
国立大学法人 北海道大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立大学法人 北海道大学 filed Critical 国立大学法人 北海道大学
Priority to JP2010505651A priority Critical patent/JPWO2009119538A1/ja
Publication of WO2009119538A1 publication Critical patent/WO2009119538A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/24—Preparation of compounds containing saccharide radicals produced by the action of an isomerase, e.g. fructose

Definitions

  • the present invention relates to a novel polypeptide and use thereof, and more specifically, the 2-position hydroxyl group of the reducing terminal sugar residue of an oligosaccharide in which the reducing terminal sugar residue is linked by a ⁇ -1,4 bond.
  • Polypeptide that catalyzes a reaction that changes the conformation of the polypeptide a method for producing the same, a polynucleotide that encodes the polypeptide and a method for using the same, and the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue using the polypeptide
  • the present invention relates to a method for producing oligosaccharides and prebiotics in which the reducing terminal sugar residue having a changed locus is bound by a ⁇ -1,4 bond.
  • Carbohydrate is a main energy source of living organisms and is a biosynthetic precursor that is converted into biological components (fatty acids, triglycerides, amino acids, nucleic acids). Carbohydrates also play an important role as structural components of connective tissue, neural tissue, bacterial cell walls, and nucleic acids. Furthermore, it has recently been clarified that sugar chains possessed by glycoproteins play an important role in various information transmissions in vivo, and are attracting attention in genetic engineering, protein engineering, sugar chain engineering, and the like.
  • Trehalose ⁇ -D-glucopyranosyl- ⁇ -D-glucopyranoside
  • Trehalose is produced by using amylose from starch using isoamylase, and then starting with amylosyl trehalose as an intermediate by the action of malto-oligosyl trehalose synthase, and this intermediate is further converted into maltooligosyl trehalose trehalohydrolase. It is produced by hydrolysis using In this production method, it is necessary to collect amylose as a reaction residue and repeat the same reaction as described above (see Non-Patent Document 1).
  • Trehalose uses maltose phosphorylase produced by a bacterium belonging to the genus Paenibacillus in the deep sea to produce ⁇ -D-glucose-1-phosphate in the presence of maltose and phosphate, and glucose is added to the reaction solution to add trehalose. It is also produced by the reverse reaction of phosphorylase (see Patent Document 4). This production method is also complicated because it requires an enzyme reaction of 2 to 4 stages, as in the above method using starch as a raw material.
  • Isomaltooligosaccharides are produced from starch by a three-stage enzymatic reaction using Bacillus ⁇ -amylase, soybean ⁇ -amylase and Aspergillus niger ⁇ -glucosidase.
  • the oligosaccharide produced by this enzyme reaction is generally a mixture of ( ⁇ -1,2, ⁇ -1,3, ⁇ -1,6) glycosidic linked saccharides with a degree of polymerization of 2-6 and contained in the mixture. It is difficult to control the composition of oligosaccharides (see Non-Patent Document 2).
  • epilactose Another example of functional oligosaccharide is epilactose.
  • Epilactose is produced using a reverse reaction of ⁇ -1,4-galactosidase derived from Bacillus circulans ATCC 31382 strain (see Non-Patent Document 3).
  • galactosyl mannose having ⁇ -1,3 bond, ⁇ -1,4 bond and ⁇ -1,6 bond is produced at about 1: 3: 1, so that pure epilactose is obtained. It is necessary to remove these by-products together with the remaining substrate by a complicated purification operation.
  • CE cellobiose 2-epimerase
  • EC 5.1.3.11 is an enzyme having an activity of catalyzing a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing terminal sugar residue of cellobiose, and is an obligate anaerobic rumen bacterium Luminocox albus.
  • R. albus 7 strains (stored as ATCC 27210) have been suggested to exist (see Non-Patent Document 5).
  • the gene coding for CE from albus NE1 was successfully cloned and its nucleotide sequence was determined.
  • the enzyme was an intracellular enzyme.
  • Cellobiose reported that O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -D-mannose In addition to producing (Glc-Man) (FIG. 1), Glc-Glc-Man (O- ⁇ -D-glucopyranosyl- (1 ⁇ 4)-) which is a rare cellooligosaccharide from cellotriose (Glc-Glc-Glc) O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -D-mannose) (FIG.
  • epimerase which is an isomerase
  • Most epimerases use saccharides modified with nucleotides, phosphates, acyl groups, etc. as substrates, while those using unmodified sugars as substrates are aldose 1-epimerase (EC 5.1.3.3).
  • aldose 1-epimerase EC 5.1.3.3
  • Maltose 1-epimerase EC 5.1.3.21
  • CE EC 5.1.3.11
  • the CE is the only epimerase that acts on the hydroxyl group at the 2-position of the reducing end sugar residue.
  • CE can be expected to be highly useful in the production of oligosaccharides because it does not produce by-products because it catalyzes a reaction that changes the conformation within the substrate molecule.
  • epimerase which is an isomerase, can be expected to have many advantages and usefulness for the synthesis of rare oligosaccharides due to its unique enzyme activity.
  • the epimerase acting on the hydroxyl group at the 2-position of the group is only one type of CE (see Non-Patent Document 4).
  • An object of the present invention is to obtain a novel polypeptide that catalyzes a reaction that changes the conformation of a hydroxyl group of an oligosaccharide, and to provide an enzymatic synthesis method of the oligosaccharide in which the conformation of the hydroxyl group is changed.
  • the present inventors newly acquired a gene encoding epimerase that catalyzes a reaction that changes the hydroxyl conformation of the oligosaccharide, and further changes the hydroxyl conformation of the oligosaccharide encoded by the gene.
  • Polypeptides that catalyze the reaction to be obtained were obtained, and the enzyme chemical properties were elucidated, and the following inventions were completed.
  • (I) (1) a polypeptide comprising the amino acid sequence represented by any of SEQ ID NOs: 1 to 4, or (2) one or more amino acids in the amino acid sequence represented by any of SEQ ID NOs: 1 to 4 Is a conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of an oligosaccharide consisting of an amino acid sequence deleted, substituted or added, and the reducing end sugar residue linked by a ⁇ -1,4 bond A polypeptide that catalyzes a reaction that changes.
  • (Iii) a polypeptide having the physicochemical properties shown in (A) to (G) below;
  • A The apparent molecular weight by SDS-PAGE is 43 to 45 kDa,
  • B having the amino acid sequence shown in SEQ ID NO: 10 at the N-terminus,
  • C specifically catalyzing a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of the oligosaccharide to which the reducing end sugar residue is bonded by a ⁇ -1,4 bond;
  • D When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 8.0,
  • E After holding at 4 ° C.
  • the enzyme activity remains at 80% or more
  • the enzyme activity remains at 80% or more
  • (V) a polypeptide having the physicochemical properties shown in (A) to (G) below;
  • A The apparent molecular weight by SDS-PAGE is 44 to 46 kDa,
  • B having the amino acid sequence shown in SEQ ID NO: 12 at the N-terminus,
  • C specifically catalyzing a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of the oligosaccharide to which the reducing end sugar residue is bonded by a ⁇ -1,4 bond;
  • D) When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 7.5,
  • E After holding at 4 ° C.
  • the enzyme activity remains 80% or more
  • (Vi) (1) a polynucleotide encoding a polypeptide comprising the amino acid sequence represented by any of SEQ ID NOs: 1 to 4, or (2) one of the amino acid sequences represented by any of SEQ ID NOs: 1 to 4 Alternatively, the oligosaccharide having the amino acid sequence in which a plurality of amino acids are deleted, substituted, or added, and the reducing terminal sugar residue of the oligosaccharide having the reducing terminal sugar residue linked by a ⁇ -1,4 bond is positioned at position 2
  • (Vii) (1) a polynucleotide comprising the nucleotide sequence represented by any of SEQ ID NOs: 5 to 8, or (2) a complementary sequence of the nucleotide sequence represented by any of SEQ ID NOs: 5 to 8 and stringent conditions Catalyzing a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of an oligosaccharide consisting of a base sequence that hybridizes with and having a reducing end sugar residue bonded by a ⁇ -1,4 bond
  • the polynucleotide according to (vi) which is any one of the polynucleotides encoding the polypeptide.
  • (X) A method for producing a polypeptide that catalyzes a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of an oligosaccharide in which the reducing end sugar residue is linked by a ⁇ -1,4 bond.
  • a step of culturing the transformant according to (ix), a step of causing the transformant to produce the polypeptide, and recovering the polypeptide from the transformant or a culture supernatant of the transformant Comprising the step of:
  • (Xi) A method for producing an oligosaccharide in which the reducing end sugar residue in which the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue is changed is bound by a ⁇ -1,4 bond, A step of incubating the polypeptide according to any one of (v) and an oligosaccharide in which a reducing terminal sugar residue is bonded by a ⁇ -1,4 bond; and a reducing terminal sugar residue of the oligosaccharide on the polypeptide.
  • a method comprising producing the oligosaccharide by catalyzing a reaction that changes the conformation of the hydroxyl group at the 2-position of the group.
  • (Xii) a method for producing a prebiotic comprising an oligosaccharide in which the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue is changed by a ⁇ -1,4 bond to the reducing end sugar residue.
  • a method comprising producing a prebiotic by catalyzing a reaction that changes a conformation of a hydroxyl group at the 2-position of a reducing terminal sugar residue of a sugar.
  • the polypeptide provided by the present invention (1) catalyzes a reaction that changes the internal conformation of a substrate molecule and does not require any reactant other than oligosaccharide. (2) Since there is no reaction by-product, purification of the target product is easy, and it is suitable for mass production of functional oligosaccharides. (3) Substrate specificity for non-reducing end sugars Since it is not strict, it has advantages such as being able to synthesize oligosaccharides that cannot be synthesized by conventional methods.
  • the polypeptide provided by the present invention is used, not only the cellooligosaccharide or epilactose in which the conformation of the 2-position hydroxyl group of the reducing end sugar residue is changed, but also the stereo of the 2-position hydroxyl group of the desired reducing end sugar residue.
  • Oligosaccharides can be synthesized easily and in large quantities in which the reducing end sugar residue having a changed conformation is bound by a ⁇ -1,4 bond. Thereby, the oligosaccharide which has a physiological effect, a prebiotic, a synbiotic, and the functional food containing these can be provided at low cost.
  • FIG. 5 is a scheme showing a reaction catalyzed by the polypeptide of the present invention to isomerize the hydroxyl group at the 2-position of glucose at the reducing end of cellobiose and convert it to Glc-Man.
  • 1 is a scheme showing a reaction catalyzed by the polypeptide of the present invention to isomerize the hydroxyl group at the 2-position of the reducing end glucose of cellotriose and convert it to Glc-Glc-Man.
  • It is a scheme showing a reaction catalyzed by the polypeptide of the present invention to isomerize the hydroxyl group at the 2-position of glucose at the reducing end of lactose and convert it to epilactose.
  • CE-NE1 (registration number BAF81108), C.I. phytofermentans-derived AGE-like protein (Cp AGE-like, registration number ABX42625), C.I. saccharolyticus-derived AGE-like protein (Cs AGE-like, registration number ABP65941); It is a figure which shows the result of carrying out multiple alignment of the amino acid sequence of fragilis origin AGE-like protein (Bf AGE-like, accession number BAD47600) using the Clustal W program. Bold amino acids in the sequence indicate two conserved regions, * below the sequence indicates amino acids that are conserved in all sequences, and ⁇ indicates a putative catalytic residue involved in the AGE reaction of Anabaena.
  • FIG. 3 is a diagram showing the result of multiple alignment of amino acid sequences of mD1, mD2, mD3, and mR6 using the Clustal W program for comparison with the amino acid sequence of CE-NE1.
  • Bold amino acids in the sequence indicate amino acids conserved in CE-NE1.
  • Lane S is a reaction product using no enzyme
  • Lane 1 is CE-NE1 (control)
  • Lane 2 is mD1
  • Lane 3 is mD2
  • Lane 4 is mD3
  • Lane 5 is mR6.
  • FIG. 3 is a diagram showing the results of analyzing the reaction product by TLC after performing an enzyme reaction using CE-NE1 and purified recombinant enzymes (mD1, mD2, mD3, mR6) using cellotetraose as a substrate.
  • Lane S is a reaction product using no enzyme
  • Lane 1 is CE-NE1 (control)
  • Lane 2 is mD1
  • Lane 3 is mD2
  • Lane 4 is mD3
  • Lane 5 is mR6.
  • FIG. 4 is a diagram showing the results of TLC analysis of a reaction product after CE-NE1 and purified recombinant enzymes (mD1, mD2, mD3, mR6) were subjected to an enzyme reaction using 4 ⁇ -mannobiose as a substrate.
  • Lane S is a reaction product using no enzyme
  • Lane 1 is CE-NE1 (control)
  • Lane 2 is mD1
  • Lane 3 is mD2
  • Lane 4 is mD3
  • Lane 5 is mR6.
  • FIG. 3 is a diagram showing the results of analyzing the reaction product by TLC after performing an enzyme reaction using CE-NE1 and purified recombinant enzymes (mD1, mD2, mD3, mR6) using globotriose as a substrate.
  • Lane S is a reaction product using no enzyme
  • Lane 1 is CE-NE1 (control)
  • Lane 2 is mD1
  • Lane 3 is mD2
  • Lane 4 is mD3
  • Lane 5 is mR6.
  • Lane 1 is glucose
  • lane 2 is mannose
  • lane 3 is galactose
  • lane 4 is fructose
  • lane 5 is xylose
  • lane 6 is arabinose as a substrate
  • the left side of each lane has no enzyme added
  • the right side has an enzyme added reaction product.
  • Analysis was conducted. It is a figure which shows the result of having analyzed the reaction product by TLC after performing the enzyme reaction which used monosaccharide as alpha-2 saccharide
  • Lane 1 was cordierbiose, lane 2 was nigerose, lane 3 was maltose, lane 4 was isomaltose as a substrate, and the left side of each lane was analyzed without any enzyme, and the right side was analyzed for the reaction product with the enzyme added. It is a figure which shows the result of having analyzed the reaction product by TLC after performing the enzyme reaction which used the monosaccharide as (beta) -2 saccharide
  • Lane 1 was sophorose
  • lane 2 was laminaribiose
  • lane 3 was cellobiose
  • lane 4 was gentiobiose as a substrate
  • the left side of each lane was analyzed without any enzyme and the right side was analyzed for the reaction product.
  • CE-NE1 and purified recombinant enzymes (mD1, mD2, mD3, mR6) were subjected to an enzymatic reaction using (A) cellobiose and (B) lactose as substrates, and then the reaction product was subjected to acid hydrolysis, and then TLC It is a figure which shows the result analyzed by.
  • Lane Std is a standard monosaccharide ((A) glucose and mannose, (B) galactose and mannose), lane 1 is CE-NE1 (control), lane 2 is mD1, lane 3 is mD2, lane 4 is mD3, lane 5 Is a reaction product using mR6. It is a figure which shows optimal pH about CE-NE1 and the purified recombinant enzyme (mD1, mD2, mD3, mR6). The vertical axis of the graph shows the relative value when the enzyme activity at pH 7.5 is 100%, and the horizontal axis of the graph shows the pH.
  • polypeptide comprising the amino acid sequence represented by any one of SEQ ID NOs: 1 to 4, or (2) 1 in the amino acid sequence represented by any one of SEQ ID NOs: 1 to 4. 2 of the reducing terminal sugar residue of an oligosaccharide having an amino acid sequence in which one or a plurality of amino acids are deleted, substituted, or added, and the reducing terminal sugar residue is linked by a ⁇ -1,4 bond.
  • a polypeptide that catalyzes a reaction that changes the conformation of a hydroxyl group.
  • the present invention also provides polypeptides having the physicochemical properties shown in (A) to (G) below:
  • D When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 7.5,
  • the enzyme activity remains 80% or more
  • the apparent molecular weight by SDS-PAGE in (A) above varies slightly depending on the degree of post-translational modification in the polypeptide used and the concentration of the gel used in SDS-PAGE. One skilled in the art will readily appreciate that it can be about 38 kDa to 48 kDa.
  • the polypeptide comprising the amino acid sequence represented by SEQ ID NO: 1 provided by the present invention is an example of a polypeptide having the physicochemical properties represented by the above (A) to (G), and based on the sequence information.
  • the calculated molecular weight is 45425.5. Further, if the position of a single band shown in lane 2 of FIG. 5 is accurately represented, the apparent molecular weight by SDS-PAGE is 43.2 kDa.
  • the present invention also provides polypeptides having the physicochemical properties shown in (A) to (G) below:
  • D When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 8.0,
  • Optimum temperature Shows an enzyme activity of 80% or more at 10 to 45 ° C. when the enzyme activity at 25 ° C. is 100%
  • the apparent molecular weight by SDS-PAGE in (A) above varies slightly depending on the degree of post-translational modification in the polypeptide used and the concentration of the gel used in SDS-PAGE, so the actual molecular weight of the polypeptide is about One skilled in the art will readily understand that it can be between 39 kDa and 49 kDa.
  • the polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2 provided by the present invention is an example of a polypeptide having the physicochemical properties represented by the above (A) to (G), and based on the sequence information.
  • the calculated molecular weight is 48346.9. Further, when the position of a single band shown in lane 3 of FIG. 5 is accurately represented, the apparent molecular weight by SDS-PAGE is 44.3 kDa.
  • the present invention further provides polypeptides having physicochemical properties shown in A) to (G) below:
  • D When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 9.0,
  • Optimum temperature Shows an enzyme activity of 80% or more at 15 to 35 ° C. when the enzyme activity at 25 ° C. is 100%, and (G) the enzyme at 30 ° C. after holding at 40 ° C. for 1 hour. The activity remains 80% or more.
  • the apparent molecular weight by SDS-PAGE varies slightly depending on the degree of post-translational modification in the polypeptide used and the concentration of the gel used for SDS-PAGE. Therefore, the actual molecular weight of the polypeptide is about 42 kDa to 52 kDa. Those skilled in the art will readily understand that this is possible.
  • the polypeptide comprising the amino acid sequence represented by SEQ ID NO: 3 provided by the present invention is an example of a polypeptide having physicochemical properties represented by the above (A) to (G), and based on the sequence information.
  • the calculated molecular weight is 46964.0. Further, if the position of a single band shown in lane 4 of FIG. 5 is accurately represented, the apparent molecular weight by SDS-PAGE is 46.7 kDa.
  • the present invention also provides polypeptides having the physicochemical properties shown in A) to (G) below:
  • D When the enzyme activity at pH 7.5 is 100%, the enzyme activity is 80% or more at pH 7.0 to 7.5,
  • the enzyme activity remains 80% or more
  • the apparent molecular weight by SDS-PAGE varies slightly depending on the degree of post-translational modification in the polypeptide used and the concentration of the gel used for SDS-PAGE. Therefore, the actual molecular weight of the polypeptide is about 40 kDa to 50 kDa. Those skilled in the art will readily understand that this is possible.
  • the polypeptide comprising the amino acid sequence represented by SEQ ID NO: 4 provided by the present invention is an example of a polypeptide having the physicochemical properties represented by the above (A) to (G), and based on the sequence information.
  • the calculated molecular weight is 49177.6. Further, when the position of a single band shown in lane 5 of FIG. 5 is accurately represented, the apparent molecular weight by SDS-PAGE is 45.4 kDa.
  • any of the above polypeptides is a polypeptide that catalyzes a reaction that changes the conformation of the hydroxyl group at the 2-position of the reducing end sugar residue of an oligosaccharide in which the reducing end sugar residue is bonded by a ⁇ -1,4 bond.
  • 2-epimerase activity means an activity that catalyzes a reaction that changes the conformation of the 2-position hydroxyl group of a reducing terminal sugar residue of an oligosaccharide.
  • “Epimerization” is intended to change the conformation of the hydroxyl group at the 2-position of the reducing terminal sugar residue of the oligosaccharide.
  • the polypeptide of the present invention exhibits 2-epimerase activity with respect to an oligosaccharide in which the reducing terminal sugar residue is bound by a ⁇ -1,4 bond, and the oligosaccharide can be 2-epimerized. It is a polypeptide.
  • the polypeptide of the present invention acts on an oligosaccharide in which a reducing terminal sugar residue is bonded by a ⁇ -1,4 bond, and the reducing terminal sugar residue is a ⁇ -1,2 bond, a ⁇ -1,3 bond, Substrate specificity that does not act on oligosaccharides linked by any of ⁇ -1,6 bond, ⁇ -1,2 bond, ⁇ -1,3 bond, ⁇ -1,4 bond, ⁇ -1,6 bond Have sex.
  • An oligosaccharide having 2 to 15 sugar residues is intended as an oligosaccharide in which a reducing terminal sugar residue is bound by a ⁇ -1,4 bond as a substrate for the polypeptide of the present invention.
  • the number of sugar residues is preferably 2 to 5, specifically cellobiose, cellotriose, cellotetraose, cellopentaose, lactose, glucosyl mannose, 4 ⁇ -mannobiose (O- ⁇ -D-mannopyranosyl- (1 ⁇ 4) -OD-mannose) or globotriose (O- ⁇ -D-galactopyranosyl- (1 ⁇ 4) -O- ⁇ -D-galactopyranosyl- (1 ⁇ 4) -D- Glucose) and the like.
  • the 2-epimerase activity possessed by the polypeptide of the present invention is a 2-epimerized oligosaccharide produced by an enzymatic reaction using an oligosaccharide having a reducing terminal sugar residue bound by a ⁇ -1,4 bond as a substrate. Can be expressed qualitatively or quantitatively.
  • the oligosaccharide in the reaction solution is analyzed by chromatography such as HPLC or TLC, the reaction product peak is identified by comparing the retention time or mobility with the standard product, and the peak area ratio or spot intensity with the standard product
  • the activity can be measured by calculating the reaction product concentration from In the case of an unknown reaction product that does not have a standard product, for example, the reaction product is decomposed into constituent sugars by acid decomposition, then separated by chromatography, and then analyzed by analyzing the concentration of reducing end sugar residues. Can be measured.
  • the present invention provides a polypeptide having 2-epimerase activity with respect to an oligosaccharide in which a reducing terminal sugar residue is bound by a ⁇ -1,4 bond.
  • the polypeptide of the present invention has 2-epimerase activity against cellobiose, but also has 2-epimerase activity against cellooligosaccharides other than lactose or cellobiose.
  • the polypeptide of the present invention having such properties is very useful for the synthesis of novel oligosaccharides or the mass production of rare oligosaccharides.
  • (D) in the physicochemical properties possessed by the polypeptide of the present invention is a property relating to so-called “optimal pH”. When the enzyme activity at 30 ° C. and pH 7.5 is 100%, the enzyme activity is 80% or more. Means a pH indicating Further, (E) in the physicochemical properties of the polypeptide of the present invention is a property relating to so-called “pH stability”. After holding the enzyme at 4 ° C. for 20 hours at various pHs, at 30 ° C. and pH 7.5. The pH range where the enzyme activity of 80% or more remains.
  • (F) in the physicochemical properties possessed by the polypeptide of the present invention is a property relating to the so-called “optimum temperature”, which is 80% or more when the enzyme activity at 25 ° C. and pH 7.5 is 100%.
  • the reaction temperature showing enzyme activity is meant.
  • (G) in the physicochemical properties of the polypeptide of the present invention is a property related to so-called “temperature stability”, and the enzyme activity at 30 ° C. and pH 7.5 after holding the enzyme at various temperatures for 1 hour. Means a temperature range in which 80% or more remains.
  • the buffer solution required for the reaction solution is preferably a sodium phosphate buffer solution or a glycylglycine-NaOH buffer solution, and the buffer solution concentration is preferably 20 to 100 mM.
  • polypeptide is used interchangeably with “peptide” or “protein”.
  • a polypeptide “fragment” is intended to be a polypeptide comprising a partial amino acid sequence of the polypeptide.
  • polypeptide of the present invention may be a polypeptide containing an amino acid sequence useful for purification of the polypeptide.
  • amino acid sequences useful for polypeptide purification include amino acid sequences that encode epitope-tagged polypeptides such as His, Myc, and Flag.
  • polypeptide of the present invention may be any polypeptide in which amino acids are peptide-bonded, but is not limited thereto, and is a polypeptide having various modifying groups such as phosphate groups and sugar chains. There may be.
  • the present invention also provides a variant of a polypeptide consisting of the amino acid sequence represented by any of SEQ ID NOs: 1 to 4.
  • a “variant” consists of an amino acid sequence in which one or more amino acids are substituted, deleted, or added in the amino acid sequences of SEQ ID NOs: 1-4. Also contemplated are polypeptides that retain 2-epimerase activity for oligosaccharides in which the reducing terminal sugar residue is linked by a ⁇ -1,4 linkage.
  • the amino acid mutation site and number in the present invention are not particularly limited as long as a polypeptide having 2-epimerase activity against an oligosaccharide in which the reducing terminal sugar residue is bound by a ⁇ -1,4 bond is provided.
  • the number of amino acids it is 1 to 80, preferably 1 to 40, more preferably 1 to 20, and still more preferably 1 to 10. If the allowable range of modification is expressed by the degree of identity of the amino acid sequence, the amino acid sequence of the protein of the present invention is 80% or more, preferably 90% or more, more preferably 95% with respect to the amino acid sequence shown in SEQ ID NO: 1. % Of identity is sufficient.
  • Preferred variants have conservative or non-conservative amino acid substitutions, deletions or additions. Silent substitution, deletion and addition are preferred, and conservative substitution is particularly preferred. These do not change the 2-epimerase activity for oligosaccharides in which the reducing terminal sugar residue of the polypeptide of the present invention is bound by a ⁇ -1,4 bond.
  • Typical conservative substitutions include mutual substitution between the hydrophobic amino acids Ala, Val, Leu, and Ile, mutual substitution of the hydroxyl amino acids Ser and Thr, mutual substitution of the acidic residues Asp and Glu, amides Type amino acids Asn and Gln, mutual substitution of basic amino acids Lys and Arg, mutual substitution of aromatic amino acids Phe and Tyr, and the like.
  • a mutant in which one or several amino acids are substituted, deleted, or added can be prepared by a known point mutation introduction method or a PCR method using DNA.
  • the object can be achieved by random mutation.
  • the method for measuring 2-epimerase activity described above does the produced mutant have 2-epimerase activity for an oligosaccharide in which the desired reducing terminal sugar residue is bound by a ⁇ -1,4 bond? It can easily be determined.
  • the present invention encodes the polypeptide of the present invention, that is, the polypeptide having 2-epimerase activity for the oligosaccharide in which the reducing terminal sugar residue described above is linked by ⁇ -1,4 bond.
  • a polynucleotide is provided.
  • the polynucleotide of the present invention can be obtained as follows.
  • DNA or RNA that serves as a template for cloning the polynucleotide of the present invention is prepared.
  • the template DNA or RNA is not particularly limited, and may be derived from, for example, a single organism or may be derived from a plurality of organisms. Therefore, for example, metagenomic DNA or RNA prepared from a natural sample such as lumen or soil by a known method can be used.
  • “Metagenome” refers to a genome directly collected from the natural world without separating and culturing (micro) organisms.
  • the “metagenomic technique” is a technique for expressing a target trait (for example, enzyme activity) by directly recombining DNA or RNA without separating (cultivating) (micro) organisms from nature and performing large-scale sequencing.
  • the metagenomic method is most effective when the sequences of the similar gene and the target gene are known to some extent, and the full-length target functional gene can be isolated and expressed by PCR.
  • Eschenfeldt et al Isolated two 2,5-diketo-D-gluconate reductases from difficult-to-cultivate microbial DNA in soil (WH Eschenfeldt et al., Appl. Environ. Microbiol., 2001). 67, 4206-4214), Bell et al. Also isolated a novel lipase from environmental biomass (PJL Bell et al., Microbiology, 2002, 148, 2283-2291). ).
  • Uchiyama and Watanabe perform metagenomic walking by PCR to isolate chitinase (T. Uchiyama and T. Watanabe, Biotechniques, 2006, Vol. 41, 183-188).
  • the primer for cloning the polynucleotide of the present invention preferably comprises a base sequence capable of specifically amplifying the polynucleotide of the present invention.
  • a part or all of a base sequence characteristic of each base sequence is selected from base sequences encoding the polypeptide of the present invention, for example, the base sequences shown in any of SEQ ID NOs: 5 to 8. Can be used as a primer.
  • the polynucleotide of the present invention can be obtained from recombinant DNA obtained by a known method such as PCR using the above template DNA or RNA and the above primer. Nucleotide sequence information from several recombinant DNA isolates can be combined to provide the coding sequence for all amino acids of the polypeptides of the invention, as well as upstream and downstream nucleotide sequences.
  • the polynucleotide of the present invention can also be produced by a chemical synthesis method such as a phosphoramidide method, or using a commercially available DNA synthesizer.
  • a preferred example of the polynucleotide of the present invention is a polynucleotide comprising the base sequence shown in any of SEQ ID NOs: 5 to 8.
  • the present invention also provides a polynucleotide that hybridizes under stringent conditions with a polynucleotide comprising a complementary sequence of the base sequence represented by any of SEQ ID NOs: 5 to 8.
  • Stringent hybridization conditions include, for example, a hybridization solution (50% formamide, 5 ⁇ SSC (150 mM NaCl, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 ⁇ Denhart.
  • the identity (%) of the base sequence it is 70% or more, preferably 80% or more, more preferably 90% or more, and still more preferably 95% or more with respect to the base sequences of SEQ ID NOs: 5 to 8, respectively. Any nucleic acid having a base sequence having identity may be used.
  • the polynucleotide of the present invention may exist in the form of DNA (for example, cDNA or genomic DNA) or RNA (for example, mRNA).
  • DNA can be double-stranded or single-stranded.
  • Single-stranded DNA or RNA can be the coding strand (also known as the sense strand) or it can be the non-coding strand (also known as the antisense strand).
  • the nucleic acid may be labeled with an enzyme such as horseradish peroxidase (HRPO), a radioisotope, a fluorescent substance, a chemiluminescent substance, or the like.
  • HRPO horseradish peroxidase
  • radioisotope a fluorescent substance
  • chemiluminescent substance or the like.
  • the polynucleotide of the present invention is obtained by adding a base sequence encoding a marker protein such as His tag, FLAG tag, or GFP added to the polypeptide of the present invention to the 5 ′ side or the 3 ′ side. Also good.
  • the polynucleotide of the present invention may have other base sequences if necessary.
  • Other base sequences include enhancer sequences, promoter sequences, ribosome binding sequences, base sequences used for the purpose of copy number amplification, base sequences encoding signal peptides, base sequences encoding other polypeptides, poly A Additional sequences, splicing sequences, replication origins, base sequences of genes that serve as selection markers, untranslated region sequences, and the like are included.
  • (III) Vector The present invention provides a vector comprising the polynucleotide of the present invention.
  • the vector of the present invention may be in any form such as circular or linear as long as it contains the above-described polynucleotide of the present invention, and even a vector used for in vitro translation can be used for recombinant expression.
  • the vector to be used may be used. Examples thereof include a recombinant expression vector into which a cDNA of a polynucleotide encoding the polypeptide of the present invention has been inserted.
  • the vector of the present invention may be used by selecting an appropriate vector according to the host to be used, and various viruses such as bacteriophage, baculovirus, retrovirus, vaccinia virus can be used in addition to the plasmid. is there.
  • the vector of the present invention is preferably capable of autonomous replication in a host, and is preferably in the form of plasmid DNA or phage DNA.
  • vectors for introducing nucleic acid into E. coli include plasmid DNA such as pBR322, pUC18, pBluescript II, commercially available expression vectors pET-23d (manufactured by Novagen), pET-28a (manufactured by Novagen), etc. , M13, ⁇ gtII, and other phage DNAs.
  • vectors for introduction into yeast include YEp13 and YCp50.
  • the recombinant vector may have other nucleotide sequences if necessary.
  • Other base sequences include an enhancer sequence, a promoter sequence, a ribosome binding sequence, a base sequence used for the purpose of amplification of copy number, a base sequence encoding a signal peptide, a base sequence encoding another polypeptide, poly A Additional sequences, splicing sequences, replication origins, base sequences of genes that serve as selection markers, and the like.
  • the expression vector preferably contains at least one selectable marker gene.
  • selectable marker genes include drug resistance genes such as ampicillin resistance gene, tetracycline resistance gene, neomycin resistance gene, kana machine resistance gene, chloramphenicol resistance gene, and intracellular biosynthesis of nutrients such as amino acids and nucleic acids.
  • drug resistance genes such as ampicillin resistance gene, tetracycline resistance gene, neomycin resistance gene, kana machine resistance gene, chloramphenicol resistance gene, and intracellular biosynthesis of nutrients such as amino acids and nucleic acids.
  • examples include genes involved, fluorescent protein genes such as GFP, and luciferase genes.
  • a method for producing a recombinant expression vector includes, but is not limited to, a method using a plasmid, phage, cosmid or the like.
  • the specific type of vector is not particularly limited, and a vector that can be expressed in a host cell can be appropriately selected. That is, according to the type of the host cell, a promoter sequence is appropriately selected in order to reliably express the polynucleotide of the present invention, and a vector in which this and the polynucleotide of the present invention are incorporated into various plasmids or the like is used as an expression vector. Good.
  • an arbitrary base sequence and a selection marker, a translation start codon and a translation stop codon are added using an appropriate synthetic DNA adapter, or an appropriate base sequence is used. It is also possible to newly generate or eliminate restriction enzyme cleavage sequences. These are within the scope of work normally performed by those skilled in the art. Experimental manuals describing various gene recombination operations in detail, including Sambrook et al. (See Molecular Cloning, a Laboratory Manual 2nd ed., Cold Spring Harbor Laboratory, New York, 1989). Can be done based on.
  • the polynucleotide can be introduced into an organism or cell, and the polypeptide of the present invention can be expressed in the organism or cell. Furthermore, if the vector of the present invention is used in a cell-free protein synthesis system, the polypeptide of the present invention can be synthesized. Thus, it can be said that the vector of the present invention should contain at least a polynucleotide encoding the polypeptide of the present invention. That is, it should be noted that vectors other than expression vectors are also included in the technical scope of the present invention.
  • the present invention provides a transformant into which the polynucleotide of the present invention has been introduced. That is, the transformant of the present invention is a transformant capable of expressing and producing the polypeptide of the present invention.
  • the polypeptide of the present invention is preferably stably expressed, but may be transiently expressed.
  • transformants are intended to include not only cells, tissues or organs but also individual organisms, but cells (especially prokaryotic cells, fungi (eg, The transformant in the present invention can be prepared by introducing the polynucleotide or vector of the present invention into an appropriate host cell.
  • Suitable microorganisms include Escherichia bacteria (more preferably Escherichia coli), Bacillus bacteria (more preferably Bacillus subtilis), and Corynebacterium genus.
  • Bacteria bacteria belonging to the genus Brevibacterium, Serratia ia) genus bacteria, Pseudomonas genus bacteria, Arthrobacter genus bacteria, Erwinia genus bacteria, Methylobacterium genus bacteria, Rhodobacter genus bacteria, Streptomyces (c) Streptomyces (c)
  • Examples include microorganisms such as microorganisms of the genus Zymomonas, yeasts of the genus Saccharomyces, etc. Particularly preferred host cells are Escherichia coli and Bacillus subtilis.
  • Introduction of the polynucleotide or vector of the present invention into a host cell can be carried out by methods known to those skilled in the art.
  • methods for introducing a vector or the like into a host cell include the calcium phosphate method, electroporation method, spheroplast method, liposome method, DEAE dextran method, lithium acetate method, junction transfer method, methods using calcium ions, and the like. It is done.
  • a fraction containing the polypeptide is collected, and a conventional method (for example, Salting-out method, ultrafiltration method, isoelectric point precipitation method, gel filtration method, electrophoresis method, ion exchange chromatography, various affinity chromatography such as hydrophobic chromatography and antibody chromatography, chromatofocusing method, adsorption chromatography
  • a conventional method for example, Salting-out method, ultrafiltration method, isoelectric point precipitation method, gel filtration method, electrophoresis method, ion exchange chromatography, various affinity chromatography such as hydrophobic chromatography and antibody chromatography, chromatofocusing method, adsorption chromatography
  • the desired polypeptide can be recovered and purified in accordance with reverse phase chromatography and the like.
  • the fraction contains transformed cells, it is possible to recover and purify the target polypeptide by combining cell disruption with the above-mentioned conventional technique.
  • the fraction isolated in the above purification process is analyzed using, for example, a bioassay specific to the polypeptide of the present invention (for example, enzymatic reaction using lactose or cellooligosaccharide as a substrate and analysis of the product). By doing so, the presence of the polypeptide of the present invention can be confirmed.
  • a bioassay specific to the polypeptide of the present invention for example, enzymatic reaction using lactose or cellooligosaccharide as a substrate and analysis of the product.
  • the polypeptide of the present invention can be purified by affinity chromatography in combination with the conventional purification method described above.
  • those having a His tag can be efficiently obtained by affinity chromatography using a nickel column, those having a Myc tag using an anti-Myc antibody, and those having a Flag tag using an anti-Flag antibody. Purification is realized.
  • the polypeptide of the present invention is expressed in a form to which a tag or other functional polypeptide is attached, the tag or functional polypeptide added using an appropriate protease (thrombin, trypsin, etc.) is cleaved, The protein of the invention can be recovered.
  • an appropriate protease thrombin, trypsin, etc.
  • polypeptide of the present invention can be prepared in a single form or in a form to which a tag or functional polypeptide is added, but is not limited thereto, and the protein used in the present invention is further limited. It is also possible to convert into various forms. For example, various chemical modifications to proteins, binding to polymers such as polyethylene glycol, binding to insoluble carriers, encapsulation in liposomes, and the like can be considered by various techniques known to those skilled in the art.
  • the polypeptide of the present invention may be obtained by an organic chemical synthesis method such as Fmoc method (fluorenylmethyloxycarbonyl method) or tBoc method (t-butyloxycarbonyl method), or a suitable commercially available peptide synthesizer.
  • an organic chemical synthesis method such as Fmoc method (fluorenylmethyloxycarbonyl method) or tBoc method (t-butyloxycarbonyl method), or a suitable commercially available peptide synthesizer.
  • Fmoc method fluorenylmethyloxycarbonyl method
  • tBoc method t-butyloxycarbonyl method
  • the present invention provides a method for producing a 2-epimerized oligosaccharide in which a reducing terminal sugar residue is bound by a ⁇ -1,4 bond.
  • the method for producing an oligosaccharide of the present invention uses the polypeptide of the present invention.
  • the method of the invention comprises incubating a polypeptide of the invention with an oligosaccharide having a reducing terminal sugar residue attached by a ⁇ -1,4 linkage.
  • the oligosaccharide is not particularly limited, but is preferably cellooligosaccharide (cellobiose, cellotriose, cellotetraose, etc.), lactose, glucosyl mannose, 4 ⁇ -mannobiose or globotriose.
  • the conditions for the catalytic reaction in the method of the present invention are not particularly limited, but can be set in consideration of the optimum conditions described above according to the polypeptide of the present invention to be used.
  • the polypeptide of the present invention can be used for a catalytic reaction in a purified state, but can also be used in a state of being immobilized on a column or in the state of the above transformant.
  • the oligosaccharide produced in the method of the present invention is purified at a mass production level by a known method such as HPLC, silica gel, activated carbon column chromatography or the like. Purification can be confirmed by measuring 2-epimerase activity by the method described above.
  • the present invention provides a method for producing prebiotics comprising 2-epimerized oligosaccharides in which the reducing terminal sugar residues are linked by ⁇ -1,4 bonds.
  • Prebiotics means “indigestible substances that have a positive impact on the health of the host by improving the balance of the intestinal flora (the group of microorganisms that live in the digestive tract (mainly anaerobic flora))” (GR Gibson and MB RobertFroid, J. Nutr., 1995, Vol. 125, pages 1401-1141, or MB Robertfroid, J. Nutr., 2007, No. 133830S-137737S. ) And as used herein, it is useful to propagate useful microorganisms (eg, probiotics such as lactic acid bacteria and bifidobacteria) in the intestinal environment of animals (including humans) Substances that promote the improvement of the internal environment are intended.
  • useful microorganisms eg, probiotics such as lactic acid bacteria and bifidobacteria
  • Typical “prebiotics” include indigestible substances such as oligosaccharides, whey fermented products by propionic acid bacteria, and dietary fiber. Oligosaccharides serve as food for probiotics, Stores intestinal bacteria and aids their growth.
  • prebiotics include absorption of minerals, suppression of blood cholesterol and neutral fat levels, prevention of arteriosclerosis, suppression of blood glucose levels, improvement of diabetes, improvement of obesity, activity of intestinal motility , Improvement of constipation, activation of immunity, prevention of infection, prevention of cancer, suppression of blood ammonia level, improvement of hepatic encephalopathy due to decreased liver function, promotion of vitamin synthesis by enteric bacteria, various minerals Include, but are not limited to, promoting the absorption of ulcer and improving the symptoms of ulcerative colitis.
  • oligosaccharide may have a mineral absorption promoting effect.
  • the mechanism of action is that oligosaccharides promote the absorption of various minerals by widening the intercellular tissue gap (so-called tight junction (TJ)) between cells inside the small or large intestine. (T. Suzuki and H. Hara, Life Sci. 2006, 79401-79410).
  • epilactose which is a stereoisomer (epimer) of the hydroxyl group at the reducing terminal sugar residue of lactose
  • the polypeptide of the present invention is capable of producing epilactose from lactose, and therefore the polypeptide of the present invention comprises a prebiotic comprising a 2-epimerized oligosaccharide in which a reducing terminal sugar residue is linked by a ⁇ -1,4 bond. Can be used to make ticks.
  • the method for producing prebiotics of the present invention uses the above polypeptide.
  • the method of the invention comprises incubating the polypeptide with a material comprising an oligosaccharide in which the reducing terminal sugar residue is linked by a ⁇ -1,4 bond.
  • the material containing the oligosaccharide is not particularly limited.
  • milk that is a natural raw material containing lactose particularly livestock milk such as cow, goat or sheep, can be used as it is or after being defatted.
  • whey (milk) fraction recovered from livestock milk, processed milk and milk beverages such as low fat milk, low protein milk, skim / deproteinized milk or low lactose milk are also compositions containing the above oligosaccharides.
  • prebiotics containing epilactose can be produced inexpensively and easily.
  • Example 1 Cloning and sequencing of gene from metagenomic DNA and RNA Cloning of CE gene from metagenomic DNA and RNA and determination of nucleotide sequence were performed according to the following method.
  • a submarine type electrophoresis layer Mupid-ex (ADVANCE, Tokyo, Japan) is used for the agarose gel electrophoresis apparatus, and a Seake GTG Agarose (Lonza, Rockland, ME) is used for the agarose for electrophoresis. did.
  • Base sequence analysis was performed by the die terminator method, and was performed by ABI PRISM 310 (Applied Biosystems, Foster City, CA) or CEQ 8000 (Beckman Coulter, Fullerton, CA).
  • the thermal cycler used was T-gradient (Biometra, Gottingen, Germany) or TaKaRa Thermalcycler Dice (Takara Bio, Kyoto, Japan).
  • the suspension was filtered through a 40 ⁇ m nylon mesh and the filtrate was centrifuged at 500 ⁇ g.
  • the collected supernatant was centrifuged (13,400 ⁇ g, 1 minute, 4 ° C.) to recover the rumen bacterial precipitate.
  • DNA was extracted from this precipitate using Isoplant II (Nippongene).
  • RNA precipitate was dissolved in 100 ⁇ L of RNase-free water and purified using RNeasy (Qiagen). The purified mRNA was concentrated using MICROB Express (Ambion). Single-stranded cDNA was synthesized from the concentrated mRNA using SuperScript III 1st Strand cDNA Synthesis kit (Invitrogen).
  • N-acetyl-D-glucosamine 2-epimerase Partial Fragment N-acetyl-D-glucosamine 2-epimerase (N-acetyl-D-glucosamine 2-epimerase, hereinafter referred to as AGE) is obtained by N-acetyl-D-glucosamine being 2-epimerized to form N -An enzyme that produces acetyl-D-mannosamine, and the three-dimensional structure is already known in pigs (registration number PDB 1F3P) and cyanobacteria Anabaena (registration number PDB 2GZ6). Therefore, for the purpose of designing a common primer suitable for amplification of the epimerase gene, R.I.
  • CE-NE1 (registration number BAF81108) derived from albus, AGE-like protein (Cp AGE-like, registration number ABX42625) derived from Clostridium phytofermentans ICDg strain, Caldicelluloslpital saccharoltics (Caldric DS03)
  • Cs AGE-like, registration number EAP43970 the amino acid sequences of the strain-derived AGE-like protein (Cs AGE-like, registration number EAP43970) and Bacteroides fragilis YCH 46-derived AGE-like protein (Bf AGE-like, registration number BAD47600) are used. Multiple aligned.
  • the single-stranded DNA of (2) when used as a sample, 100 ng of DNA, 12.5 ⁇ L of Ampdirect Plus (Shimadzu), 1 U of TaKaRa Ex Taq polymerase (Takara Bio) or Nova Taq Hot Start DNA polymerase (Merck) and PCR with 25 ⁇ L of the PCR reaction solution prepared with 6.25 pmol of each of the primers univ-f and univ-r.
  • the DNA thermal cycler was set to be cooled at 4 ° C. after 30 cycles of 94 ° C. for 30 seconds, 48 ° C. for 30 seconds, 72 ° C. for 30 seconds, followed by extension reaction at 72 ° C. for 4.5 minutes.
  • the extracted DNA of (1) was digested with EcoRI, HindIII, and PstI for 2 hours, respectively, and self-circulation (self-ligation) reaction was performed overnight using DNA Ligation Convenience kit (Nippongene).
  • DNA Ligation Convenience kit (Nippongene).
  • PCR reaction solution prepared by 25 ⁇ L.
  • the DNA thermal cycler is set to be set at 40 ° C for 30 cycles at 94 ° C, 30 seconds at 60 ° C, 2 minutes at 72 ° C, followed by extension reaction at 72 ° C for 5 minutes and then cooled at 4 ° C. did.
  • the amplified fragments by nested PCR were separated by electrophoresis (1.0% agarose gel) and recovered using Recochip (Takara Bio). Each recovered amplified fragment was subcloned into a pGEM-T vector (Promega), and the nucleotide sequence was determined.
  • a PCR reaction solution prepared by 100 ⁇ g of the extracted DNA (1), 1 U TaKaRa Ex Taq polymerase, and 1 ⁇ PCR buffer solution (containing 2 mM MgCl 2 , 0.2 mM dNTP, 20 pmol of each of the above primer sets), and further PCR Went.
  • the DNA thermal cycler was set to be cooled at 4 ° C. after 35 cycles of 94 ° C. for 30 seconds, 56 ° C. for 30 seconds, and 72 ° C. for 2 minutes, followed by 72 ° C. for 5 minutes.
  • the amplified DNA fragments were subcloned into the pGEM-T vector to obtain recombinant plasmids pGEM-md1, pGEM-md2, pGEM-md3 and pGEM-mr6 containing full length md1, md2, md3, mr6, respectively.
  • the base sequence was determined.
  • the base sequence of md1 and the deduced amino acid sequence of the protein encoded by it are shown in SEQ ID NO: 5 and SEQ ID NO: 1, and the base sequence of the ORF contained in md2 and the protein encoded by it (denoted as mD2)
  • the amino acid sequences are SEQ ID NO: 6 and SEQ ID NO: 2
  • the nucleotide sequence of the ORF contained in md3 and the deduced amino acid sequence of the protein encoded by it (denoted as mD3) are shown in SEQ ID NO: 7 and SEQ ID NO: 3
  • the ORF contained in mr6 SEQ ID NO: 8 and SEQ ID NO: 4 show the deduced amino acid sequences of the nucleotide sequences of and the protein encoded thereby (denoted as mR6), respectively.
  • Example 2 Construction and purification of protein mD1, mD2, mD3, mR6 expression system (1) Construction of expression plasmid Construction of an expression vector for expressing proteins mD1, mD2, mD3, mR6 using E. coli as a host Therefore, the following primers were designed.
  • PCR was performed in combination with pGEM-mr6, and restriction enzyme recognition sites were introduced at both ends of each ORF (md1: NdeI-XhoI, md2: NdeI-EcoRI, md3: NdeI-XhoI, md6: NdeI-XhoI). PCR was performed by 25 cycles of reaction at 98 ° C. for 10 seconds, 55 ° C.
  • E. coli BL21 (DE3) was introduced, and a transformant was selected on an LB agar medium containing ampicillin having a final concentration of 100 ⁇ g / mL, and pre-cultured overnight at 37 ° C. in the same liquid medium 10 mL. 200 mL of the same liquid medium placed in a 500 mL Erlenmeyer flask was inoculated with 0.5 mL of the preculture solution (total 800 mL), and cultured with shaking at 37 ° C. and 160 rpm.
  • isopropyl- ⁇ -D-thiogalactoside is added to a final concentration of 0.1 mM to induce expression of the target protein. Further, shaking culture was performed at 20 ° C. for 20 hours.
  • the crude enzyme solution was added to a coupled column of TOYOPEARL CM-650M (Tosoh Bioscience) and DEAE Sepharose Fast Flow (GE Healthcare Bio-Sciences) equilibrated with buffer A in advance. After washing with buffer A, the TOYOPEARL CM-650M column was separated, and the protein adsorbed on the DEAE-Sepharose column was eluted with a 0 to 500 mM NaCl linear concentration gradient and fractionated to 50 by 5 mL. Each fraction was subjected to SDS-PAGE, and the fraction in which the recombinant protein was most eluted was collected as a purified fraction, and then dialyzed in buffer A.
  • TOYOPEARL CM-650M Tosoh Bioscience
  • DEAE Sepharose Fast Flow GE Healthcare Bio-Sciences
  • VIVASPIN 20 VIVASPIN 20 (VIVASCIENCE). An equal amount of glycerol was added to the concentrate and stirred well, and then stored as a purified recombinant enzyme at ⁇ 20 ° C. until use.
  • SDS-polyacrylamide gel electrophoresis of recombinant enzyme SDS-PAGE was performed according to the method of Laemmli (Nature, 1970, Vol. 227, pages 680-685). MiniProtean III (Bio-Rad) was used for the electrophoresis apparatus. The separation gel had an acrylamide concentration of 10% (gel thickness of 0.75 mm), and electrophoresis was performed at a constant current of 15 mA. The gel after electrophoresis was stained using Bio-Safe CBB G-250 Stain (Bio-Rad). SDS-PAGE Standard, Low range (Bio-Rad) was used as the standard protein. Control CE-NE1 was prepared according to the method described in Non-Patent Document 1.
  • N-terminal amino acid sequences of mD1, mD2, mD3, and mR6 were identified as MFVEEIKKDLVED (SEQ ID NO: 9), MDLKTMSEQMKEH (SEQ ID NO: 10), MKNEVVYKQL (SEQ ID NO: 11), and MVQTMIKEMQ (SEQ ID NO: 12), respectively.
  • MFVEEIKKDLVED SEQ ID NO: 9
  • MDLKTMSEQMKEH SEQ ID NO: 10
  • MKNEVVYKQL SEQ ID NO: 11
  • MVQTMIKEMQ SEQ ID NO: 12
  • the estimated molecular weight was calculated using Compute pI / Mw (http://kr.expasy.org/tools/pi_tool.html) based on the deduced amino acid sequences of mD1, mD2, mD3, and mR6.
  • the molecular weights of mD1, mD2, mD3, and mR6 are 45425.5 (SEQ ID NO: 1; number of amino acids, 389), 48346.9 (SEQ ID NO: 2; number of amino acids, 412), 46964.0 (SEQ ID NO: 3; amino acids) 405), 49177.6 (SEQ ID NO: 4; number of amino acids, 423), which was close to the results of SDS-PAGE.
  • R.I The molecular weight of CE-NE1 of albus NE1 is around 43.1 kDa (calculated molecular weight, 45217.4; number of amino acids, 389).
  • Isoelectric point The isoelectric point (pI) based on the deduced amino acid sequence was calculated using Compute pI / Mw. As a result, the isoelectric points of mD1, mD2, mD3, and mR6 were calculated as pH 4.99, 4.83, 4.82, and 4.89, respectively. According to Non-Patent Document 1, R.I. The calculated isoelectric point of CE-NE1 of albus NE1 is pH 4.69.
  • mD1 is derived from Coprococcus eutactus ATCC 27759-derived hypothetical protein (AGE-like) (registration number EDP27130) and 65%, Fecalibacterium prasunithizine AG (Faecalactiplatinium ApitrophizinMig. No. EDP22108) and 60%, and C.I. Phytofermentans ISDg-derived AGE (registration number ABX42625) showed 59% identity.
  • R. Albus NE1 strain and ATCC 27210 strain CE (registration numbers BAF81108 and BAF81109) showed 51% identity.
  • MD2 is C.I. eutactus ATCC 27759-derived hypothetical protein (like AGE) (registration number EDP27130) and 55%, C.I. Phytofermentans ISDg-derived AGE-like protein (registration number ABX42625) and 55%, F.I. Prausnitzii M21 / 2-derived hypothetical protein (AGE-like) (registration number ABP6594) and 50%, C.I. Saccharolyticus DSM8903-derived AGE-like protein (registration number EDP27130) showed 45% identity.
  • R. Albus NE1 and ATCC 27210 CE (BAF81108 and BAF81109) showed 44% identity.
  • MD3 is C.I. eutactus ATCC 27759-derived hypothetical protein (AGE) (registration number EDP22108), 54%, F.E. Prausnitzii M21 / 2-derived hypothetical protein (AGE-like) (registration number ABP6594) and 51%, C.I. Phytofermentans ISDg-derived AGE-like protein (registration number ABX42625) showed 50% identity.
  • R. Albus NE1 and ATCC27210 CE (registration numbers BAF81108 and BAF81109) showed 46% identity.
  • MR6 is a Bacteroides uniformis ATCC 8492 derived hypothetical protein (AGE) (registration number EDO52282) and 57%. fragilis NCTC 9343-derived hypothetical protein (AGE-like) (registration number CAH06520) and 56%. fragilis YCH46-derived AGE-like protein (registration number BAD47600) was 56%, and Parabacteroides disstasonis ATCC8503-derived AGE-like protein (registration number ABR41852) was 54% identical. R. Albus NE1 and ATCC 27210 CE (registration numbers BAF81108 and BAF81109) showed 38% identity.
  • FIG. 6 shows multiple alignment of the deduced amino acid sequence of CE-NE1 (registration number BAF81108) and the deduced amino acid sequences of mD1, mD2, mD3, and mR6.
  • the deduced amino acid sequences of mD1, mD2, mD3, and mR6 showed 50.9, 45.5, 46.6, and 40.9% identity, respectively, with that of CE-NE1.
  • HPLC system LC-2000 Plus (JASCO) Guard column: SUGAR SP-G (6.0 mm ⁇ 50 mm, Shodex) Separation column: SUGAR SP0810 (8.0 mm ⁇ 300 mm, Shodex) Eluent: Water Flow rate: 0.8 mL / min Column temperature: 80 ° C. Detection: vaporized light scattering detector (ELD2000ES; Alltech Associates, Deerfield, IL), temperature 115 ° C., gas flow rate 3.2 l / min
  • a calibration curve was prepared using epilactose (Sigma). It calculated relatively from the area of the peak derived from epilactose (elution time) and the peak derived from maltitol (elution time). Protein was quantified according to the Bradford method (MM Bradford, Anal. Biochem., 1976, 72, 248-254). A calibration curve was prepared using bovine serum albumin.
  • TLC thin layer chromatography
  • FIG. 7 shows the results when cellobiose was used as a substrate
  • FIG. 8 shows the results of cellotriose
  • FIG. 9 shows the results of cellotetraose
  • FIG. 10 shows the results of lactose
  • FIG. 11 shows the results of 4 ⁇ -mannobiose.
  • the results are shown in FIG. mD1, mD2, mD3 produced products from cellobiose, cellotriose, cellotetraose, lactose, 4 ⁇ -mannobiose and globotriose.
  • the product was detected from cellobiose, cellotriose, lactose, 4 ⁇ -mannobiose and globotriose, and no product was detected from cellotetraose.
  • the product mobility was identical to CE-NE1. Therefore, Glc-Man (O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -D-mannose) is obtained from cellobiose, and Glc-Glc-Man (O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) is obtained from cellotriose.
  • -O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -D-mannose) is obtained from cellotetraose by Glc-Glc-Glc-Man (O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -O— ⁇ -D-glucopyranosyl-O- ⁇ -D-glucopyranosyl- (1 ⁇ 4) -D-mannose) is derived from lactose by epilactose (O- ⁇ -D-galactopyranosyl- (1 ⁇ 4) -D -Mannose) is Man-Glc (O- ⁇ -D-mannopyranosyl- (1 ⁇ 4) -D-glucose) from 4 ⁇ -mannobiose and O- ⁇ - from globotriose. - galactopyranosyl - (1 4) -O- ⁇ -D- galactopyranosyl - (1 4) -D-
  • the silica gel in the region containing the reaction product on the TLC plate was scraped and extracted with 30 mL of water. This was centrifuged at 8000 ⁇ g for 10 minutes, the supernatant was filtered with a 0.22 ⁇ m syringe filter (ADVANTEC), and the filtrate was concentrated with a freeze dryer FD-1000 (EYELA).
  • the composition ratio was estimated to be 1: 1 from the color intensity (FIG. 17).
  • the oligosaccharide produced from cellobiose is Glc-Man
  • the oligosaccharide produced from lactose is epilactose
  • mD1, mD2, mD3, and mR6 have the same 2-epimerase activity as CE-NE1.
  • the obtained epilactose is an anomer of ⁇ and ⁇
  • the product is epilactose from the chemical shift of the peak of the 13 C-NMR spectrum. Identified.
  • Optimum temperature The enzyme activities of mD1, mD2, mD3, and mR6 were measured at each temperature (20, 30, 40, 50, 60, 70 ° C.). Except for the reaction temperature, the activity was measured in the phosphate buffer according to the conditions of (6). As a result, mD1, mD2, mD3, and mR6 are maximum at about 25 ° C. (FIG. 20A), 20-40 ° C. (FIG. 20B), 25-35 ° C. (FIG. 20C), and around 30-45 ° C. (FIG. 20D), respectively. Showed activity. The maximum activity of CE-NE1 was observed around 30 ° C.
  • mD2 was an enzyme having a relative activity of 50% even at 0 ° C. and a remarkable activity even in the low temperature region. Further, mR6 showed a relative activity of 60% or more even at 50 ° C., and was an enzyme that acts even in a high temperature region.
  • Example 4 Prebiotic production test using commercially available milk Using mR6, a prebiotic production test containing epilactose was conducted. Enzymatic reaction is performed by adding 10 ⁇ l (about 1 ⁇ g) of mR6 to 490 ⁇ l of commercially available milk, and the reaction is performed at 30 ° C. for 1 hour, 2 hours, 3 hours, 4 hours, and room temperature for 24 hours. It was. The reaction solution was diluted 10-fold with water and boiled for 10 minutes, and then the supernatant obtained by centrifugation at 15000 ⁇ g for 10 minutes was analyzed by TLC. Except for the above, the conditions of (7) of Example 3 were all followed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention a pour objet un nouveau polypeptide capable de catalyser une réaction destinée à modifier la conformation d'un groupe hydroxy dans un oligosaccharide et de proposer un procédé de synthèse enzymatique pour un oligosaccharide ayant un groupe hydroxy dont la conformation est altérée. Un polypeptide quelconque choisi parmi les polypeptides (1) et (2) suivants est décrit : (1) un polypeptide comprenant une séquence d'acides aminés illustrée dans l'une quelconque des SEQ ID No 1 à 4 ; et (2) un polypeptide qui comprend une séquence d'acides aminés portant une délétion, une substitution ou une addition d'un ou de plusieurs résidus acides aminés dans une séquence d'acides aminés illustrée dans l'une quelconque des SEQ ID No 1 à 4, qui peut catalyser une réaction destinée à modifier la conformation d'un groupe hydroxy à la position 2 dans un résidu  sucre réducteur terminal d'un oligosaccharide, le résidu sucre réducteur terminal étant lié par une liaison β-1,4.
PCT/JP2009/055742 2008-03-25 2009-03-24 Nouveau polypeptide ayant une activité épimérase, son procédé de production, et utilisation WO2009119538A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2010505651A JPWO2009119538A1 (ja) 2008-03-25 2009-03-24 エピメラーゼ活性を有する新規ポリペプチド、その製造方法ならびにその利用方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008-077017 2008-03-25
JP2008077017 2008-03-25

Publications (1)

Publication Number Publication Date
WO2009119538A1 true WO2009119538A1 (fr) 2009-10-01

Family

ID=41113730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/055742 WO2009119538A1 (fr) 2008-03-25 2009-03-24 Nouveau polypeptide ayant une activité épimérase, son procédé de production, et utilisation

Country Status (2)

Country Link
JP (1) JPWO2009119538A1 (fr)
WO (1) WO2009119538A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040407A1 (en) * 2009-02-05 2012-02-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Cellobiose 2-epimerase, its preparation and uses

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 2 October 2007 (2007-10-02), ITO, S. ET AL.: "Definition: Ruminococcus albus CE gene for cellobiose 2-epimerase, complete cds, strain: NE1", retrieved from http://www.ncbi.nlm.nih.gov/ entrez/viewer.fcgi?157889439:DD BJ:7244314 Database accession no. AB301953 *
DATABASE GENBANK 2 October 2007 (2007-10-02), ITO,S. ET AL.: "Definition: cellobiose 2-epimerase [Ruminococcus albus]", retrieved from http://www.ncbi.nlm.nih.gov/ entrez/viewer.fcgi?157889440:DD BJ:7244314 Database accession no. BAF81108 *
HIDENORI TAGUCHI ET AL.: "Prebiotics Tokusei o Yusuru Epilactose no Seisei Koso: Seisan Kin no Bunri · Dotei no Seisei Koso no Tokusei", NIPPON NOGEI KAGAKUKAI 2009 NENDO (HEISEI 21 NENDO) TAIKAI KOEN YOSHISHU, 5 March 2009 (2009-03-05), pages 45 *
ITO C. ET AL.: "Ruminococcus albus Yurai Cellobiose 2-epimerase no Cloning Oyobi Sho Seishitsu no Kaimei", JOURNAL OF APPLIED GLYCOSCIENCE KOEN YOSHISHU, vol. 55, no. 217, 20 June 2008 (2008-06-20), pages 55 *
ITO S. ET AL.: "Cloning and sequencing of the cellobiose 2-epimerase gene from an obligatory anaerobe, Ruminococcus albus.", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 360, no. 3, 2007, pages 640 - 645 *
TAGUCHI H. ET AL.: "Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens.", FEMS MICROBIOL LETT., vol. 287, no. L, October 2008 (2008-10-01), pages 34 - 40 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120040407A1 (en) * 2009-02-05 2012-02-16 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Cellobiose 2-epimerase, its preparation and uses
US9175282B2 (en) 2009-02-05 2015-11-03 Hayashibara Co., Ltd. Cellobiose 2-epimerase, its preparation and uses

Also Published As

Publication number Publication date
JPWO2009119538A1 (ja) 2011-07-21

Similar Documents

Publication Publication Date Title
Jørgensen et al. Enzymatic conversion of D-galactose to D-tagatose: heterologous expression and characterisation of a thermostable L-arabinose isomerase from Thermoanaerobacter mathranii
KR101473918B1 (ko) 사이코스 에피머화 효소, 이의 제조방법 및 이를 이용한 사이코스의 제조방법
US20180023073A1 (en) Aldolase, aldolase mutant, and method and composition for producing tagatose by using same
JP5098086B2 (ja) ケトース３−エピメラーゼとその製造方法並びに用途
US8802393B2 (en) Arabinose isomerase expressed from Corynebacterium genus and tagatose manufacturing method by using it
KR101480422B1 (ko) 효소조합 반응에 의한 과당으로부터 타가토스 생산 방법 및 그 조성물
Iqbal et al. Characterization of a heterodimeric GH2 β-galactosidase from Lactobacillus sakei Lb790 and formation of prebiotic galacto-oligosaccharides
CN111712570A (zh) 一种生产阿洛酮糖及其衍生物的工程菌株及其构建方法和应用
EP3438256B1 (fr) 3-épimérase et polynucléotide la codant
US20080124771A1 (en) Food Grade Thermophilic Arabinose Isomerase Expressed from Gras, and Tagatose Manufacturing Method By Using It
US7235712B1 (en) Bacterial isolates of the genus Klebiella, and an isomaltulose synthase gene isolated therefrom
CN110438112B (zh) 一种d-阿洛酮糖-3-差向异构酶的突变体及其应用
Zhang et al. A novel Lactococcus lactis l-arabinose isomerase for d-tagatose production from lactose
KR102448351B1 (ko) 알룰로스 에피머화 효소 변이체, 이의 제조방법 및 이를 이용한 알룰로스의 제조방법
Yi et al. Cloning of dextransucrase gene from Leuconostoc citreum HJ-P4 and its high-level expression in E. coli by low temperature induction
EP2843044A1 (fr) Variante améliorée de D-psicose 3-épimerase et utilisations associées
WO2009119538A1 (fr) Nouveau polypeptide ayant une activité épimérase, son procédé de production, et utilisation
Xu et al. Identification of a highly thermostable mannitol 2-dehydrogenase from Caldicellulosiruptor morganii Rt8. B8 and its application for the preparation of D-mannitol
Yamashita et al. Isolation, characterization, and molecular cloning of a thermostable xylitol oxidase from Streptomyces sp. IKD472
US20100041106A1 (en) Recombinant gras strains expressing thermophilic arabinose isomerase as an active form and method of preparing food grade tagatose by using the same
Li et al. Identification and characterization of a novel high-activity amylosucrase from Salinispirillum sp. LH10-3-1
CN104073481B (zh) 一种耐酸性提高的l-阿拉伯糖异构酶突变体
Ren et al. Gene expression and molecular characterization of a thermostable trehalose phosphorylase from Thermoanaerobacter tengcongensis
Chen Enzymatic Conversion of D-Psicose From D-Glucose by the Co-Expression of D-Psicose 3-Epimerase and Glucose Isomerase
KR101237857B1 (ko) 신규한 알파-엘-아라비노퓨라노시데이즈 및 그 효소를 이용한 반섬유소 아라비난으로부터 아라비노스의 제조 방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09724208

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2010505651

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09724208

Country of ref document: EP

Kind code of ref document: A1